Table 1.

Clinical trials results from epidiolex-focused studies.

Condition	Drug Dosage	% Symptom Reduction	% Adverse Effects	Study Size	Citation
Lennox-Gastaut Syndrome	20 mg/kg/day, titrated over 11 days	43.9%	86%	n = 156	Thiele et al., 2018
Dravet Syndrome	20 mg/kg/day, titrated over 11 days	43%	93%	n = 108	Devinsky et al., 2017
Parkinson’s Disease	20 mg/kg/day, titrated by 2.5–5 mg/kg at 3–5 day intervals	NA	100%	n = 13	Leehey, 2019
Ulcerative Colitis	50–200 mg/day	28%	96.6%	n = 60	Irving et al., 2018
Cannabis Use Disorder	Up to 800 mg/day	0%	NA	n = 4	Hill, 2016
Opioid Use Disorder	400 mg/day or 800 mg/day	100%	66.7%	n = 10	Gonzalez-Cuevas et al., 2018
Cognitive Dysfunction	600 mg/day	0%	71.4%	n = 36	Boggs et al., 2018

Clinical trial results from Epidiolex-focused studies: The table summarizes the results from the currently completed clinical trials that have tested Epidiolex’s efficacy against various conditions. The % symptom reduction is reported as the percentage of patients in the treatment group to report improvement in the treatment of their condition. Similarly, the % of adverse effects refers to the total percentage of treatment group patients that reported any adverse effect. The sample size describes the number of patients that have completed the clinical trial currently.